3,501 results match your criteria Hemophilia Acquired

Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice.

J Blood Med 2022 11;13:255-265. Epub 2022 May 11.

Department of Pediatrics, Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

In acquired hemophilia A (AHA), autoantibodies to coagulation factor VIII (FVIII) neutralize FVIII activity leading to a potentially severe bleeding diathesis that carries a high rate of morbidity and mortality. This disorder is rare and occurs mainly in adults over 60 years of age or in the postpartum period. The diagnosis should be suspected in patients with new-onset bleeding without a personal or family history of bleeding and can be confirmed via specific assays for FVIII inhibitors. Read More

View Article and Full-Text PDF

Naturally Occurring Anti-Idiotypic Antibodies Portray a Largely Private Repertoire in Immune-Mediated Thrombotic Thrombocytopenic Purpura.

J Immunol 2022 May 18. Epub 2022 May 18.

Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; and Department for BioMedical Research, University of Bern, Bern, Switzerland

Rare immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-threatening disease resulting from a severe autoantibody-mediated ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motifs, member 13) deficiency. Acute iTTP episodes are medical emergencies, but when treated appropriately >95% of patients survive. However, at least half of survivors will eventually experience a relapse. Read More

View Article and Full-Text PDF

Use of thromboelastography before the administration of hemostatic agents to safely taper recombinant activated factor VII in acquired hemophilia A: a report of three cases.

Thromb J 2022 May 16;20(1):28. Epub 2022 May 16.

Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.

Background: Acquired hemophilia A (AHA) is a rare autoimmune disease characterized by bleeding events. Recombinant activated factor VII (rFVIIa) is a first-line bypassing agent, which is effective against clinically significant bleeding. However, there is no standard way of tapering and discontinuing rFVIIa, mainly because there is no established method for monitoring rFVIIa therapy for AHA. Read More

View Article and Full-Text PDF

Effect of different incubation times on the detection of factor VIII inhibitor in acquired hemophilia A.

Clin Chem Lab Med 2022 May 16. Epub 2022 May 16.

Department of Clinical Laboratory, The First Hospital of China Medical University, Shenyang, P.R. China.

View Article and Full-Text PDF

Acquired Hemophilia as a Paraneoplastic Syndrome in a Patient With Small Cell Lung Carcinoma.

Cureus 2022 Apr 7;14(4):e23926. Epub 2022 Apr 7.

Hematology Oncology, State University of New York (SUNY) Upstate Medical University, Syracuse, USA.

This case report describes a 72-year-old female patient diagnosed with small cell lung carcinoma who was found to have elevated partial thromboplastin time (PTT) after reporting diarrhea and melanotic stool. Further investigations revealed the presence of a factor VIII inhibitor, possibly resulting from a side effect of immunotherapy or of possible paraneoplastic origin. The patient's PTT remained elevated following a course of steroid treatment, raising the likelihood of paraneoplastic etiology. Read More

View Article and Full-Text PDF

Acquired hemophilia as a rare cause of excessive bleeding during dentistry: report of two cases and short review.

Arch Clin Cases 2022 6;9(1):12-18. Epub 2022 Apr 6.

Department of Emergency Medicine, EvK Wesel, Germany.

Acquired hemophilia is a rare coagulation disorder that is not diagnosed by routine clinical laboratory tests. Thus, many perioperative or acute emergent bleeding complications remain unclear until the underlying cause is specified. We report two cases of postoperative bleeding in the context of dental surgery in which subsequent acquired hemophilia could be confirmed and present a short review from the literature. Read More

View Article and Full-Text PDF

Acquired bleeding disorders.

Haemophilia 2022 May;28 Suppl 4:68-76

Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Acquired bleeding disorders can accompany hematological, neoplastic, autoimmune, cardiovascular or liver diseases, but can sometimes also arise spontaneously. They can manifest as single factor deficiencies or as complex hemostatic abnormalities. This review addresses (a) acquired hemophilia A, an autoimmune disorder characterized by inhibitory autoantibodies against coagulation factor VIII; (b) acquired von Willebrand syndrome in patients with cardiovascular disorders, where shear stress abnormalities result in destruction of von Willebrand factor; and (c) liver function disorders that comprise complex changes in pro- and anti-hemostatic factors, whose clinical implications are often difficult to predict. Read More

View Article and Full-Text PDF

Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome-Multicenter, Real-Life Long-Term Follow-Up.

Front Immunol 2022 19;13:843718. Epub 2022 Apr 19.

Clinical Immunology, Angioedema and Allergy Unit, The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel.

Background: Antiphospholipid syndrome (APS) is an acquired hypercoagulable condition associated with antiphospholipid antibody (aPL) presence. Data on re-thrombosis following APS-diagnosis are limited.

Methods: This is a retrospective analysis of new thrombotic events among primary APS (pAPS) patients followed for up to 15 years in three medical centers in Israel. Read More

View Article and Full-Text PDF

Platelet function testing: Current practice among clinical centres in Northern Europe.

Haemophilia 2022 May 5. Epub 2022 May 5.

Coagulation Disorders Unit, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.

Introduction: Platelet function tests are used to screen and diagnose patients with possible inherited platelet function defects (IPFD). Some acquired platelet dysfunction may be caused by certain drugs or comorbidities, which need to be excluded before testing.

Aims: To identify current practice among centres performing platelet function tests in Northern Europe. Read More

View Article and Full-Text PDF

Acquired hemophilia A following SARS CoV-2 mRNA vaccine: Correspondence.

J Oncol Pharm Pract 2022 May 4:10781552221082575. Epub 2022 May 4.

Dr DY Patil University, Pune, India.

View Article and Full-Text PDF

Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report.

J Med Case Rep 2022 May 3;16(1):177. Epub 2022 May 3.

Division of Hospital Medicine, Department of Internal Medicine, The Ohio State University, M112 Starling Loving Hall, 320 W. 10th Avenue, Columbus, OH, 43210, USA.

Background: Acquired hemophilia A is a disorder caused by autoantibodies against coagulation factor VIII that may present with severe bleeding. We report a rare case of acquired hemophilia A presenting with coexisting lupus anticoagulant.

Case Presentation: An 81-year-old Caucasian female presented with large ecchymoses over the torso and extremities in the setting of an enoxaparin bridge to warfarin. Read More

View Article and Full-Text PDF

Case Report: Acquired Haemophilia A Following mRNA-1273 Booster Vaccination Against SARS-CoV-2 With Concurrent Diagnosis of Pleomorphic Dermal Sarcoma.

Front Immunol 2022 11;13:868133. Epub 2022 Apr 11.

Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.

While the global pandemic caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is still ongoing and new virus variants are emerging, there is a universal need for vaccines to protect individuals from severe complications and ideally control the pandemic by enabling herd immunity. Several vaccines against SARS-CoV-2 have been approved and are widely used to stem the recurring waves of coronavirus disease 2019 (COVID-19). Post-marketing surveillance is essential to record even rare safety issues related to these new vaccines. Read More

View Article and Full-Text PDF

Bleeding disorders in implant dentistry: a narrative review and a treatment guide.

Int J Implant Dent 2022 Apr 16;8(1):20. Epub 2022 Apr 16.

Department of Oral- and Maxillofacial Surgery, University Medical Center Mainz, Augustusplatz 2, 55131, Mainz, Germany.

Purpose: Considering a high prevalence of congenital and especially acquired bleeding disorders, their heterogeneity and the multitude of possible treatments strategies, a review of the scientific data on this topic is needed to implement a treatment guide for healthcare professionals.

Methods: A selective literature review was performed via PubMed for articles describing oral surgery / dental implant procedures in patients with congenital and acquired bleeding disorders. Out of the existing literature, potential treatment algorithms were extrapolated. Read More

View Article and Full-Text PDF

Postpartum-acquired hemophilia A: Experience from a tertiary center in South India.

Int J Gynaecol Obstet 2022 Apr 9. Epub 2022 Apr 9.

Department of Clinical Hematology, Amrita Institute of Medical Sciences, Cochin, India.

View Article and Full-Text PDF

Acquired haemophilia A associated to autoimmune thyroiditis and pangastritis.

BMJ Case Rep 2022 Apr 8;15(4). Epub 2022 Apr 8.

Internal Medicine, Hospital Beatriz Angelo, Loures, Lisboa, Portugal.

Acquired haemophilia A is a rare condition defined by the presence of coagulation inhibitors, which are autoantibodies directed against factor VIII that interfere with its activity. We report a case of a 69-year-old woman that presented with knee haemarthrosis followed by spontaneous retroperitoneal haematoma. On coagulation studies, she presented normal prothrombin time with prolonged activated partial thromboplastin time non-correcting on mixture test, low titers of factor VIII and was detected factor VIII inhibitor that led to diagnosis of acquired haemophilia A. Read More

View Article and Full-Text PDF

A Case of Acquired Hemophilia A in a Patient with Exposure to COVID-19.

Case Rep Hematol 2022 22;2022:9494249. Epub 2022 Mar 22.

Department of Hematology and Medical Oncology, Baylor Scott & White Medical Center, Texas A&M University College of Medicine, Temple, TX, USA.

Acquired Hemophilia A (AHA) is a very rare autoimmune condition involving immune-mediated depletion of Factor VIII, resulting in spontaneous hemorrhage. Failure to recognize AHA as a possible etiology of hemorrhage can result in delayed diagnosis and treatment. The COVID-19 pandemic has given rise to several hematologic conditions and complications, with a rare manifestation being Acquired Hemophilia A (AHA). Read More

View Article and Full-Text PDF

Recombinant porcine factor VIII in acquired hemophilia A: Experience from two patients and literature review.

Res Pract Thromb Haemost 2022 Feb 27;6(2):e12688. Epub 2022 Mar 27.

School of Medicine University of Colorado Anschutz Medical Campus Aurora Colorado USA.

Background: Acquired hemophilia A (AHA) is a disease caused by antibody formation inhibiting the function of factor VIII, causing bleeding. Recombinant porcine factor VIII (rpFVIII) escapes human FVIII antibody recognition and can provide life-saving hemostasis. However, the development of antibodies against pFVIII can limit its use. Read More

View Article and Full-Text PDF
February 2022

Time is Blood: The Impact of Diagnostic Delays on Acquired Hemophilia A.

Cureus 2022 Feb 9;14(2):e22048. Epub 2022 Feb 9.

Division of Stem Cell Transplantation and Cellular Therapies, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center/Harvard Medical School, Boston, USA.

Background and objective Acquired hemophilia A (AHA) is an uncommon autoimmune bleeding disorder caused by the formation of neutralizing antibodies against endogenous factor VIII (FVIII). Delays between the onset of symptoms and the correct diagnosis of the condition lead to poor outcomes and a higher mortality rate. In this study, we aimed to analyze the impact of delays in diagnosis on AHA patients. Read More

View Article and Full-Text PDF
February 2022

Acquired Hemophilia A: A Permanent Challenge for All Physicians.

Medicines (Basel) 2022 Mar 2;9(3). Epub 2022 Mar 2.

Department of General, Visceral- and Transplant Surgery, Medical Center University Duisburg-Essen, 45147 Essen, Germany.

Acquired hemophilia A (AHA) is a rare disease with a prevalence in Europe of 1.5 per million. This diagnosis is significantly delayed in about one-third of all cases, leading to deferred treatment. Read More

View Article and Full-Text PDF

A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination.

J Formos Med Assoc 2022 Mar 14. Epub 2022 Mar 14.

Division of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:

Acquired hemophilia is a rare disease resulting from autoantibodies against endogenous factor VIII (FVIII), which associates with bleeding and a high mortality rate. The pathophysiology is still unclear. Recent studies suggest genetic and environmental factors trigger the breakdown of immune tolerance. Read More

View Article and Full-Text PDF

Acquired hemophilia A following allogeneic stem cell transplantation for acute lymphoblastic leukemia.

Ann Hematol 2022 Mar 21. Epub 2022 Mar 21.

Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, K1H 8L6, Canada.

View Article and Full-Text PDF

[Acquired hemophilia]

Rev Fac Cien Med Univ Nac Cordoba 2022 03 7;79(1):57-60. Epub 2022 Mar 7.

Hospital Privado Universitario de Córdoba.

Introduction: Acquired hemophilia is a hemostasis disorder that occurs due to the presence of inhibitory autoantibodies that are directed against coagulation factor VIII. Clinically, it is manifested by spontaneous bleeding mainly in the skin and soft tissues, and unlike hereditary hemophilia ,the presence of hemarthrosis is infrequent. Although many cases are idiopathic, secondary causes must be sought since their treatment is key in the prognosis of the disease. Read More

View Article and Full-Text PDF

Uncontrollable bleeding after tooth extraction from asymptomatic mild hemophilia patients: two case reports.

BMC Oral Health 2022 03 13;22(1):69. Epub 2022 Mar 13.

The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, 237 Luoyu Road, Wuhan, 430079, China.

Background: Uncontrollable bleeding after tooth extraction usually occurs in patients with coagulation diseases, including hemophilia, von Willebrand's disease, vitamin K deficiency, platelet deficiency, and taking anticoagulant drugs. Hemophilia A is an X-linked recessive disorder caused by insufficiency of coagulation factor VIII. Mild hemophilia, defined by factor level between 0. Read More

View Article and Full-Text PDF

Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.

Haemophilia 2022 May 13;28(3):515-519. Epub 2022 Mar 13.

Haematology Department, University Hospital of Wales, Cardiff, UK.

Introduction: Acquired haemophilia A (AHA) is a rare bleeding disorder caused by development of auto-antibodies to endogenous coagulation factor VIII (FVIII). Recombinant porcine factor VIII (rpFVIII) is currently licensed only for the management of bleeding in patients with AHA. Regular monitoring of rpFVIII is recommended to assess treatment effectiveness. Read More

View Article and Full-Text PDF

Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib.

J Neurol Surg Rep 2022 Jan 8;83(1):e19-e22. Epub 2022 Mar 8.

Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States.

Spontaneous spinal subdural hematomas (SSH) are rare occurrences that can occur most commonly secondary to vascular malformations or coagulopathies. Only a small fraction of spontaneous SSHs are caused by acquired coagulation disorders such as leukemia, hemophilia, and thrombocytopenia. This case report describes a patient with a history of Guillain-Barré syndrome (GBS), hemophilia A, and mantle cell lymphoma, on zanubrutinib therapy, a Bruton tyrosine kinase inhibitor associated with a risk of spontaneous hemorrhage. Read More

View Article and Full-Text PDF
January 2022

Acquired Hemophilia A Post-COVID-19 Vaccination: A Case Report and Review.

Cureus 2022 Feb 4;14(2):e21909. Epub 2022 Feb 4.

Hematology and Oncology, Houston Methodist Hospital, Houston, USA.

Acquired hemophilia A (AHA) is an inhibitory coagulopathy that represents a rare variant of hemorrhagic syndromes. We present a case of idiopathic AHA in a 75-year-old male patient with a cutaneous hematoma that could be attributed to a recent COVID-19 vaccination. The aim of this report is to raise awareness of a possible association between AHA and COVID-19 vaccination and to review similar reported cases and management plans to prevent the development of possible morbidity and debilitating complications. Read More

View Article and Full-Text PDF
February 2022

[Examination of the effect of immunosuppressive therapy on acquired hemophilia A in elderly patients with bloodstream infections].

Nihon Ronen Igakkai Zasshi 2022 ;59(1):90-95

Department of Internal Medicine, Kohsei Chuo General Hospital.

Aim: Acquired hemophilia A (AHA) is an acquired autoantibody (inhibitor) against blood coagulation factor VIII (FVIII) that significantly reduces FVIII activity and causes a bleeding tendency. Immune acquired coagulation factor deficiency. The peak age of onset is in the 70s. Read More

View Article and Full-Text PDF

Case of acquired haemophilia a in Southeast Asia following COVID-19 vaccine.

BMJ Case Rep 2022 Mar 9;15(3). Epub 2022 Mar 9.

Department of Geriatrics, Hospital Selayang, Batu Caves, Selangor, Malaysia.

Acquired haemophilia A (AHA) is a rare bleeding disorder with high morbidity and mortality, but it is eminently treatable if diagnosis and treatment are prompt. We report a case of AHA in Southeast Asia following the administration of the Pfizer-BioNTech COVID-19 vaccine. A man in his 80s developed multiple bruises 2 weeks after his first dose of the COVID-19 vaccine. Read More

View Article and Full-Text PDF

Acquired Hemophilia A Developed Post COVID-19 Vaccine: An Extremely Rare Complication.

J Med Cases 2022 Jan 17;13(1):1-4. Epub 2022 Jan 17.

Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by circulating autoantibodies (inhibitor) directed against coagulation factor VIII (FVIII). We report a 39-year-old single female who presented to emergency department with sudden onset gross hematuria 10 days following her first dose of Pfizer-BioNTech severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA (coronavirus disease 2019 (COVID-19)) vaccine. Coagulation profile revealed isolated prolongation of the activated partial thromboplastin time due to FVIII deficiency with normal von Willebrand factor and activity. Read More

View Article and Full-Text PDF
January 2022

Acquired haemophilia A secondary to metastatic prostate cancer.

Med Clin (Barc) 2022 Feb 17. Epub 2022 Feb 17.

Servicio de Oncología Médica, Hospital Universitario de Salamanca, Salamanca, España; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España; Facultad de Medicina, Universidad de Salamanca, Salamanca, España.

View Article and Full-Text PDF
February 2022